  0 Table of Contents |
  1 CELIDA Recommendations |
| 2 Downloads |
| 3 Change Log |
 4 Artifacts Summary |
 4.1 Abdominal Positioning |
| 4.2 Antithrombotic prophylaxis with Certoparin |
| 4.3 Antithrombotic prophylaxis with Dalteparin |
| 4.4 Antithrombotic prophylaxis with Enoxaparin |
| 4.5 Antithrombotic prophylaxis with Fondaparinux |
| 4.6 Antithrombotic prophylaxis with Nadroparin |
| 4.7 Antithrombotic prophylaxis with Tinzaparin |
| 4.8 No Therapeutic Anticoagulation Treatment with Argatroban |
| 4.9 No Therapeutic Anticoagulation Treatment with Certoparin |
| 4.10 No Therapeutic Anticoagulation Treatment with Dalteparin |
| 4.11 No Therapeutic Anticoagulation Treatment with Dalteparin |
| 4.12 No Therapeutic Anticoagulation Treatment with Dalteparin |
| 4.13 No Therapeutic Anticoagulation Treatment with Enoxaparin |
| 4.14 No Therapeutic Anticoagulation Treatment with Enoxaparin |
| 4.15 NO Therapeutic Anticoagulation Treatment with Fondaparinux |
| 4.16 No Therapeutic Anticoagulation Treatment with Nadroparin |
| 4.17 No Therapeutic Anticoagulation Treatment with Tinzaparin |
| 4.18 No Therapeutic Anticoagulation Treatment with UFH |
| 4.19 Prophylactic Anticoagulation Treatment with UFH subcutaneous |
| 4.20 Therapeutic Anticoagulation Treatment UFH |
| 4.21 Therapeutic Anticoagulation Treatment with Argatroban |
| 4.22 Therapeutic Anticoagulation Treatment with Certoparin |
| 4.23 Therapeutic Anticoagulation Treatment with Dalteparin |
| 4.24 Therapeutic Anticoagulation Treatment with Dalteparin |
| 4.25 Therapeutic Anticoagulation Treatment with Dalteparin |
| 4.26 Therapeutic Anticoagulation Treatment with Enoxaparin |
| 4.27 Therapeutic Anticoagulation Treatment with Enoxaparin |
| 4.28 Therapeutic Anticoagulation Treatment with Fondaparinux |
| 4.29 Therapeutic Anticoagulation Treatment with Nadroparin |
| 4.30 Therapeutic Anticoagulation Treatment with Tinzaparin |
| 4.31 Abdominal positioning for ventilated patients with ARDS and a PaO2/FiO2 < 150 mmHg |
| 4.32 Abdominal positioning plan in case of ARDS and a PaO2/FiO2 < 150 mmHg |
| 4.33 Anticoagulation Plan for hospitalized intensive-care COVID-19 patients with no specific indication |
| 4.34 Antithrombotic prophylaxis with Fondaparinux |
| 4.35 Antithrombotic prophylaxis with LWMH |
| 4.36 No therapeutic anticoagulation for intensive care COVID-19 patients with no specific indication |
| 4.37 PEEP for ventilated COVID-19 patients |
| 4.38 PEEP Intervention Plan for Population: Ventilated COVID-19 Patients, inspiratory oxygen fraction currently 0.0 |
| 4.39 PEEP Intervention Plan for Population: Ventilated COVID-19 Patients, inspiratory oxygen fraction currently 0.4 |
| 4.40 PEEP Intervention Plan for Population: Ventilated COVID-19 Patients, inspiratory oxygen fraction currently 0.5 |
| 4.41 PEEP Intervention Plan for Population: Ventilated COVID-19 Patients, inspiratory oxygen fraction currently 0.6 |
| 4.42 PEEP Intervention Plan for Population: Ventilated COVID-19 Patients, inspiratory oxygen fraction currently 0.7 |
| 4.43 PEEP Intervention Plan for Population: Ventilated COVID-19 Patients, inspiratory oxygen fraction currently 0.8 |
| 4.44 PEEP Intervention Plan for Population: Ventilated COVID-19 Patients, inspiratory oxygen fraction currently 0.9 |
| 4.45 PEEP Intervention Plan for Population: Ventilated COVID-19 Patients, inspiratory oxygen fraction currently 1.0 |
| 4.46 Prophylactic anticoagulation in hospitalized COVID-19 patients |
| 4.47 Therapeutic anticoagulation in non-intensive care, high-risk COVID-19 patients |
| 4.48 Therapeutic Anticoagulation Plan (hospitalised, non-intensive care, COVID-19 patients with no renal function impairment (eGFR >= 30ml/min)) |
| 4.49 Tidal volume / end-inspiratory airway pressure for ventilated COVID-19 patients with ARDS |
| 4.50 Tidal volume for ventilated patients with ARDS |
| 4.51 Ventilation Plan for COVID-19 patients with ARDS |
| 4.52 Ventilation Plan for patients with ARDS |
| 4.53 CODEX-CELIDA |
| 4.54 KontaktArtDe |
| 4.55 Hospitalised COVID-19 patients, treated on ICU, without thrombembolic complication |
| 4.56 Population: Hospitalised COVID-19 patients with existing contraindications to LWMH |
| 4.57 Population: Hospitalised COVID-19 patients without contraindications to LWMH |
| 4.58 Population: Hospitalised COVID-19 patients without the need for intensive care therapy considered high-risk for developing venous thrombosis |
| 4.59 Population: Ventilated COVID-19 Patients with ARDS |
| 4.60 Population: Ventilated COVID-19 Patients with severe ARDS |
| 4.61 Population: Ventilated COVID-19 Patients, inspiratory oxygen fraction currently 0.0 |
| 4.62 Population: Ventilated COVID-19 Patients, inspiratory oxygen fraction currently 0.4 |
| 4.63 Population: Ventilated COVID-19 Patients, inspiratory oxygen fraction currently 0.5 |
| 4.64 Population: Ventilated COVID-19 Patients, inspiratory oxygen fraction currently 0.6 |
| 4.65 Population: Ventilated COVID-19 Patients, inspiratory oxygen fraction currently 0.7 |
| 4.66 Population: Ventilated COVID-19 Patients, inspiratory oxygen fraction currently 0.8 |
| 4.67 Population: Ventilated COVID-19 Patients, inspiratory oxygen fraction currently 0.9 |
| 4.68 Population: Ventilated COVID-19 Patients, inspiratory oxygen fraction currently 1.0 |
 4.69 Population: Ventilated patients with ARDS |
|